1. BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils. Issue 11 (20th April 2017) Authors: Smiljkovic, D.; Blatt, K.; Stefanzl, G.; Dorofeeva, Y.; Skrabs, C.; Focke‐Tejkl, M.; Sperr, W. R.; Jaeger, U.; Valenta, R.; Valent, P. Journal: Allergy Issue: Volume 72:Issue 11(2017:Nov.) Page Start: 1666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils. Issue 11 (20th April 2017) Authors: Smiljkovic, D.; Blatt, K.; Stefanzl, G.; Dorofeeva, Y.; Skrabs, C.; Focke‐Tejkl, M.; Sperr, W. R.; Jaeger, U.; Valenta, R.; Valent, P. Journal: Allergy Issue: Volume 72:Issue 11(2017:Nov.) Page Start: 1666 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Midostaurin: a magic bullet that blocks mast cell expansion and activation. (30th August 2017) Authors: Valent, P.; Akin, C.; Hartmann, K.; George, T. I.; Sotlar, K.; Peter, B.; Gleixner, K. V.; Blatt, K.; Sperr, W. R.; Manley, P. W.; Hermine, O.; Kluin-Nelemans, H. C.; Arock, M.; Horny, H.-P.; Reiter, A.; Gotlib, J. Journal: Annals of oncology Issue: Volume 28:Number 10(2017) Page Start: 2367 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P1013: OVERALL SURVIVAL IN PATIENTS WITH SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NEOPLASM TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 903 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P1014: OVERALL SURVIVAL IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR CLADRIBINE. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 904 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P1015: DURATION OF TREATMENT AND REDUCTION IN SERUM TRYPTASE LEVELS IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED WITH AVAPRITINIB VERSUS BEST AVAILABLE THERAPY. (23rd June 2022) Authors: Reiter, A.; Gotlib, J.; Álvarez-Twose, I.; Radia, D. H.; Luebke, J.; Bobbili, P. J.; Wang, A.; Norregaard, C.; Dimitrijević, S.; Sullivan, E.; Louie-Gao, M.; Schwaab, J.; Galinsky, I. A.; Perkins, C.; Sperr, W. R.; Sriskandarajah, P.; Chin, A.; Sendhil, S. R.; Duh, M. S.; Valent, P. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 905 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Prevalence of anxiety and depression in people with different types of cancer or haematologic malignancies: a cross-sectional study. (17th October 2022) Authors: Zeilinger, E. L.; Oppenauer, C.; Knefel, M.; Kantor, V.; Schneckenreiter, C.; Lubowitzki, S.; Krammer, K.; Popinger, C.; Kitta, A.; Kum, L.; Adamidis, F.; Unseld, M.; Masel, E. K.; Füreder, T.; Zöchbauer-Müller, S.; Bartsch, R.; Raderer, M.; Prager, G.; Krauth, M. T.; Sperr, W. R. Journal: Epidemiology and psychiatric sciences Issue: Volume 31(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Issue 10 (19th May 2014) Authors: Valent, P.; Escribano, L.; Broesby‐Olsen, S.; Hartmann, K.; Grattan, C.; Brockow, K.; Niedoszytko, M.; Nedoszytko, B.; Oude Elberink, J. N. G.; Kristensen, T.; Butterfield, J. H.; Triggiani, M.; Alvarez‐Twose, I.; Reiter, A.; Sperr, W. R.; Sotlar, K.; Yavuz, S.; Kluin‐Nelemans, H. C.; Hermine, O.... Journal: Allergy Issue: Volume 69:Issue 10(2014:Oct.) Page Start: 1267 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Proteome analysis identifies L1CAM/CD171 and DPP4/CD26 as novel markers of human skin mast cells. Issue 1 (25th May 2016) Authors: Gschwandtner, M.; Paulitschke, V.; Mildner, M.; Brunner, P. M.; Hacker, S.; Eisenwort, G.; Sperr, W. R.; Valent, P.; Gerner, C.; Tschachler, E. Journal: Allergy Issue: Volume 72:Issue 1(2017:Jan.) Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Issue 6 (17th April 2014) Authors: Hoermann, G.; Gleixner, K. V.; Dinu, G. E.; Kundi, M.; Greiner, G.; Wimazal, F.; Hadzijusufovic, E.; Mitterbauer, G.; Mannhalter, C.; Valent, P.; Sperr, W. R. Journal: Allergy Issue: Volume 69:Issue 6(2014:Jun.) Page Start: 810 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗